BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21214269)

  • 1. Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ΔEGFR.
    Chumbalkar V; Latha K; Hwang Y; Maywald R; Hawley L; Sawaya R; Diao L; Baggerly K; Cavenee WK; Furnari FB; Bogler O
    J Proteome Res; 2011 Mar; 10(3):1343-52. PubMed ID: 21214269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.
    Latha K; Li M; Chumbalkar V; Gururaj A; Hwang Y; Dakeng S; Sawaya R; Aldape K; Cavenee WK; Bogler O; Furnari FB
    Int J Cancer; 2013 Feb; 132(3):509-20. PubMed ID: 22729867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.
    Garnett J; Chumbalkar V; Vaillant B; Gururaj AE; Hill KS; Latha K; Yao J; Priebe W; Colman H; Elferink LA; Bogler O
    Neoplasia; 2013 Jan; 15(1):73-84. PubMed ID: 23359207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma.
    Nishikawa R; Sugiyama T; Narita Y; Furnari F; Cavenee WK; Matsutani M
    Brain Tumor Pathol; 2004; 21(2):53-6. PubMed ID: 15700833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.
    Huang HS; Nagane M; Klingbeil CK; Lin H; Nishikawa R; Ji XD; Huang CM; Gill GN; Wiley HS; Cavenee WK
    J Biol Chem; 1997 Jan; 272(5):2927-35. PubMed ID: 9006938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forced dimerization increases the activity of ΔEGFR/EGFRvIII and enhances its oncogenicity.
    Hwang Y; Chumbalkar V; Latha K; Bogler O
    Mol Cancer Res; 2011 Sep; 9(9):1199-208. PubMed ID: 21775422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.
    Inda MM; Bonavia R; Mukasa A; Narita Y; Sah DW; Vandenberg S; Brennan C; Johns TG; Bachoo R; Hadwiger P; Tan P; Depinho RA; Cavenee W; Furnari F
    Genes Dev; 2010 Aug; 24(16):1731-45. PubMed ID: 20713517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.
    Narita Y; Nagane M; Mishima K; Huang HJ; Furnari FB; Cavenee WK
    Cancer Res; 2002 Nov; 62(22):6764-9. PubMed ID: 12438278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.
    Mukasa A; Wykosky J; Ligon KL; Chin L; Cavenee WK; Furnari F
    Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2616-21. PubMed ID: 20133782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells.
    Fernandes H; Cohen S; Bishayee S
    J Biol Chem; 2001 Feb; 276(7):5375-83. PubMed ID: 11087732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway.
    Prigent SA; Nagane M; Lin H; Huvar I; Boss GR; Feramisco JR; Cavenee WK; Huang HS
    J Biol Chem; 1996 Oct; 271(41):25639-45. PubMed ID: 8810340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells.
    Kapoor GS; Zhan Y; Johnson GR; O'Rourke DM
    Mol Cell Biol; 2004 Jan; 24(2):823-36. PubMed ID: 14701753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
    Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
    Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.
    Fan QW; Cheng CK; Gustafson WC; Charron E; Zipper P; Wong RA; Chen J; Lau J; Knobbe-Thomsen C; Weller M; Jura N; Reifenberger G; Shokat KM; Weiss WA
    Cancer Cell; 2013 Oct; 24(4):438-49. PubMed ID: 24135280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth.
    Huang PH; Miraldi ER; Xu AM; Kundukulam VA; Del Rosario AM; Flynn RA; Cavenee WK; Furnari FB; White FM
    Mol Biosyst; 2010 Jul; 6(7):1227-37. PubMed ID: 20461251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly.
    O'Rourke DM; Nute EJ; Davis JG; Wu C; Lee A; Murali R; Zhang HT; Qian X; Kao CC; Greene MI
    Oncogene; 1998 Mar; 16(9):1197-207. PubMed ID: 9528862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis.
    Nagane M; Coufal F; Lin H; Bögler O; Cavenee WK; Huang HJ
    Cancer Res; 1996 Nov; 56(21):5079-86. PubMed ID: 8895767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity.
    Gomez GG; Volinia S; Croce CM; Zanca C; Li M; Emnett R; Gutmann DH; Brennan CW; Furnari FB; Cavenee WK
    Cancer Res; 2014 Mar; 74(5):1429-39. PubMed ID: 24436148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases.
    Nagane M; Levitzki A; Gazit A; Cavenee WK; Huang HJ
    Proc Natl Acad Sci U S A; 1998 May; 95(10):5724-9. PubMed ID: 9576951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.